388P Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC)

Junji Tsurutani, William Jacot, Toshinari Yamashita, Farhan Riaz, Rinat Yerushalmi, S-A. Im, Naoki Niikura, U. Halser-Strub, Javier Cortés, A-K. Wennstig, Y.S. Chae, X. Wang, Wěi Li, H. Simon, Giovanna Masci, Emiliano Tamburini, C. Orbegoso Aguilar, Kristen M. Tecson, Lotus Yung, Shanu Modi